Education
About Us
Working with TipRanks
Follow Us
Medpace Holdings (MEDP)
NASDAQ:MEDP
177Lu-Betabart
Cervical Cancer, Ovarian Cancer, Colorectal Cancer, Castration-Resistant Prostate Cancer (Crpc), Endometrial Cancer, Esophageal Squamous Cell Carcinoma (Escc), Nsclc (Non-Small Cell Lung Cancer), Tnbc, Triple Negative Breast Cancer, Small Cell Lung Cancer (Sclc ), Head &Amp; Neck Squamous Cell Carcinoma (Hnscc)
Phase I/II
Not Yet Recruiting
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Sep 11, 2025
―
177Lu-Tlx250
Ccrcc, Renal Cell Carcinoma (Rcc), Renal Cell Carcinoma (Kidney Cancer), Renal Cell Cancer Metastatic, Renal Cell Cancer, Recurrent, Clear Cell Renal Cell Cancer (Ccrcc)
Phase III
Not Yet Recruiting
Study of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
Aug 18, 2025
―
Rad101 (18F-Fpia)
Brain Metastases From Solid Tumors
Phase II
Recruiting
Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
Dec 19, 2024
―
Lutetium (177Lu) Rhpsma 10.1 And Pluvicto®
Metastatic Prostate Cancer
Early Phase I
Terminated
A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
Jun 17, 2024
―
Sevasemten
Becker Muscular Dystrophy
Phase II
Enrolling By Invitation
Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
Sep 27, 2023
―
Tnx-103
Pulmonary Hypertension
Phase III
Recruiting
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
Aug 01, 2023
―
Chs-006 (Anti-Tigit), Toripalimab (Anti-Pd-1)
Non-small Cell Lung Cancer, Advanced Solid Tumor, Hepatocellular Carcinoma
Phase I
Terminated
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Jan 02, 2023
―
Sevasemten 10 Mg, Sevasemten 5 Mg, Sevasemten 12.5 Mg
Becker Muscular Dystrophy
Phase II
Active Not Recruiting
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
Mar 14, 2022
―
Sevasemten
Becker Muscular Dystrophy
Phase I
Completed
A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy
Dec 02, 2021
―
Meropenem, Cefepime-Zidebactam (Fep-Zid)
Acute Pyelonephritis, Complicated Urinary Tract Infection
Phase III
Completed
Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
Jul 05, 2021
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Medpace Holdings (MEDP) have in its pipeline
MEDP is currently developing the following drugs: 177Lu-Betabart, 177Lu-Tlx250, Rad101 (18F-Fpia). These drug candidates are in various stages of clinical development as the company works toward FDA approval.